- Home
- Publications
- Publication Search
- Publication Details
Title
Residual macrovascular risk in 2013: what have we learned?
Authors
Keywords
Residual cardiovascular risk, Atherogenic dyslipidaemia, Type 2 diabetes, Therapeutic options
Journal
Cardiovascular Diabetology
Volume 13, Issue 1, Pages 26
Publisher
Springer Nature
Online
2014-01-24
DOI
10.1186/1475-2840-13-26
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel Formulation of a Reconstituted High-Density Lipoprotein (CSL112) Dramatically Enhances ABCA1-Dependent Cholesterol Efflux
- (2013) Svetlana Diditchenko et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists
- (2013) Jean-Charles Fruchart Cardiovascular Diabetology
- Dual Peroxisome Proliferator-Activated Receptor / Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
- (2013) B. Cariou et al. DIABETES CARE
- Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting
- (2013) E. Angeloni et al. EUROPEAN HEART JOURNAL
- Relationship of Lipoproteins to Cardiovascular Events
- (2013) John R. Guyton et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial
- (2013) Theodore M. Brasky et al. JNCI-Journal of the National Cancer Institute
- Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update
- (2013) Ž. Reiner NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials
- (2012) Doralisa Morrone et al. ATHEROSCLEROSIS
- Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
- (2012) Alexander Tenenbaum et al. Cardiovascular Diabetology
- Cholesterol Efflux and Atheroprotection
- (2012) Robert S. Rosenson et al. CIRCULATION
- Reversibility of Fenofibrate Therapy-Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants
- (2012) J. C. Mychaleckyj et al. DIABETES CARE
- Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial
- (2012) G. Reyes-Soffer et al. DIABETES CARE
- Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience
- (2012) D. E. Bonds et al. DIABETOLOGIA
- Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease
- (2012) Christian Besler et al. EMBO Molecular Medicine
- Association Between Omega-3 Fatty Acid Supplementation and Risk of Major Cardiovascular Disease Events
- (2012) Evangelos C. Rizos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The PCSK9 decade
- (2012) Gilles Lambert et al. JOURNAL OF LIPID RESEARCH
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
- (2012) James M. McKenney et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
- (2012) Anette Varbo et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
- (2012) Robert P Giugliano et al. LANCET
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
- (2012) Benjamin F Voight et al. LANCET
- Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Rafael Lozano et al. LANCET
- The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females
- (2012) Michel P Hermans et al. Lipids in Health and Disease
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
- (2012) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serum Phospholipid Fatty Acids and Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial
- (2011) T. M. Brasky et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
- The HDL proteome in acute coronary syndromes shifts to an inflammatory profile
- (2011) Khalid Alwaili et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males
- (2011) Michel P Hermans et al. Cardiovascular Diabetology
- Triglycerides and Cardiovascular Disease
- (2011) Michael Miller et al. CIRCULATION
- Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment: The FIELD Study
- (2011) R.-D. Ting et al. DIABETES CARE
- Effects of the New Dual PPAR / Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
- (2011) B. Cariou et al. DIABETES CARE
- Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
- (2011) M. John Chapman et al. EUROPEAN HEART JOURNAL
- Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk
- (2011) Lisa M Younk et al. Expert Opinion on Drug Metabolism & Toxicology
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
- (2011) Colin Baigent et al. LANCET
- Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control
- (2010) Vincent J. Carey et al. AMERICAN JOURNAL OF CARDIOLOGY
- High-Density Lipoprotein-Mediated Anti-Atherosclerotic and Endothelial-Protective Effects: A Potential Novel Therapeutic Target in Cardiovascular Disease
- (2010) Christian Besler et al. CURRENT PHARMACEUTICAL DESIGN
- Non-LDL-related dyslipidaemia and coronary risk: a case-control study
- (2010) Gerd Assmann et al. Diabetes & Vascular Disease Research
- Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
- (2010) T. M. E. Davis et al. DIABETOLOGIA
- “Atherogenic index of plasma” (log10 triglyceride/high-density lipoprotein−cholesterol) predicts high blood pressure, diabetes, and vascular events
- (2010) Altan Onat et al. Journal of Clinical Lipidology
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
- (2010) Min Jun et al. LANCET
- Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
- (2010) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
- (2010) Daan Kromhout et al. NEW ENGLAND JOURNAL OF MEDICINE
- Major Lipids, Apolipoproteins, and Risk of Vascular Disease
- (2009) The Emerging Risk Factors Collaboration* JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study
- (2009) Robert R Henry et al. LANCET
- Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
- (2009) Kushwin Rajamani et al. LANCET
- Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner
- (2009) Tsukasa Nakamura et al. PHARMACOLOGICAL RESEARCH
- Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
- (2008) Christopher P. Cannon et al. AMERICAN HEART JOURNAL
- Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)
- (2008) Yasushi Saito et al. ATHEROSCLEROSIS
- Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins
- (2008) Sanjay Patel et al. ATHEROSCLEROSIS
- Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone
- (2008) M J Forrest et al. BRITISH JOURNAL OF PHARMACOLOGY
- The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
- (2008) Jean-Charles Fruchart et al. Diabetes & Vascular Disease Research
- Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
- (2008) R. Scott et al. DIABETES CARE
- Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
- (2008) Anne B. Rossebø et al. NEW ENGLAND JOURNAL OF MEDICINE
- Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
- (2008) John J.P. Kastelein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial
- (2007) Bela F. Asztalos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started